In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasis.

[1]  M. Cano,et al.  Cell Cycle, Telomeres, and Telomerase in Leishmania spp.: What Do We Know So Far? , 2021, Cells.

[2]  J. Kulbacka,et al.  Therapeutic role of vanillin receptors in cancer. , 2021, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[3]  S. Kwofie,et al.  The Search for Putative Hits in Combating Leishmaniasis: The Contributions of Natural Products Over the Last Decade , 2021, Natural Products and Bioprospecting.

[4]  E. S. Coimbra,et al.  Synthesis and biological activity of novel 4-aminoquinoline/1,2,3-triazole hybrids against Leishmania amazonensis. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  E. S. Coimbra,et al.  Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis , 2021, Medical Microbiology and Immunology.

[6]  M. Islam,et al.  Vanillin Exerts Therapeutic Effects against Hyperglycemia-Altered Glucose Metabolism and Purinergic Activities in Testicular Tissues of Diabetic Rats. , 2021, Reproductive toxicology.

[7]  Luiza F O Gervazoni,et al.  Use of Natural Products in Leishmaniasis Chemotherapy: An Overview , 2020, Frontiers in Chemistry.

[8]  R. Pádua,et al.  Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis , 2020, Parasitology research.

[9]  E. S. Coimbra,et al.  Antileishmanial compounds from Connarus suberosus: Metabolomics, isolation and mechanism of action , 2020, PloS one.

[10]  S. Chua,et al.  Vanillin inhibits PqsR-mediated virulence in Pseudomonas aeruginosa. , 2020, Food & function.

[11]  J. Lago,et al.  Potential of the natural products against leishmaniasis in Old World - a review of in-vitro studies , 2020, Pathogens and global health.

[12]  Kátia da Silva Calabrese,et al.  A Triazole Hybrid of Neolignans as a Potential Antileishmanial Agent by Triggering Mitochondrial Dysfunction , 2019, Molecules.

[13]  G. Serban.  Future Prospects in the Treatment of Parasitic Diseases: 2-Amino-1,3,4-Thiadiazoles in Leishmaniasis , 2019, Molecules.

[14]  I. Demarchi,et al.  Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review , 2018, Dermatology research and practice.

[15]  E. S. Coimbra,et al.  Antileishmanial activity of a 4-hydrazinoquinoline derivative: Induction of autophagy and apoptosis-related processes and effectiveness in experimental cutaneous leishmaniasis. , 2018, Experimental parasitology.

[16]  G. Banerjee,et al.  Vanillin biotechnology: the perspectives and future. , 2018, Journal of the science of food and agriculture.

[17]  R. J. Alves,et al.  Antileishmanial activity of a naphthoquinone derivate against promastigote and amastigote stages of Leishmania infantum and Leishmania amazonensis and its mechanism of action against L. amazonensis species , 2018, Parasitology Research.

[18]  S. Sundar,et al.  Chemotherapeutics of visceral leishmaniasis: present and future developments , 2017, Parasitology.

[19]  R. López-Vélez,et al.  Drug resistance and treatment failure in leishmaniasis: A 21st century challenge , 2017, PLoS neglected tropical diseases.

[20]  L. Gedamu,et al.  Immune Response and Protective Efficacy of a Heterologous DNA-Protein Immunization with Leishmania Superoxide Dismutase B1 , 2017, BioMed research international.

[21]  R. Arenas,et al.  Leishmaniasis: a review , 2017, F1000Research.

[22]  Olivier Michielin,et al.  SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules , 2017, Scientific Reports.

[23]  A. López-Arencibia,et al.  Perifosine Mechanisms of Action in Leishmania Species , 2017, Antimicrobial Agents and Chemotherapy.

[24]  J. Lindoso,et al.  Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study. , 2015, The American journal of tropical medicine and hygiene.

[25]  N. Aronson,et al.  Leishmaniasis: treatment updates and clinical practice guidelines review , 2015, Current opinion in infectious diseases.

[26]  V. Cardoso,et al.  Antileishmanial activity and evaluation of the mechanism of action of strychnobiflavone flavonoid isolated from Strychnos pseudoquina against Leishmania infantum , 2015, Parasitology Research.

[27]  Ines Kevric,et al.  New World and Old World Leishmania Infections: A Practical Review. , 2015, Dermatologic clinics.

[28]  G. Dalekos,et al.  Leishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatment , 2015, Journal of translational internal medicine.

[29]  Douglas E. V. Pires,et al.  pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.

[30]  S. Sundar,et al.  An update on pharmacotherapy for leishmaniasis , 2015, Expert opinion on pharmacotherapy.

[31]  V. Cardoso,et al.  An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis , 2014, International journal of nanomedicine.

[32]  A. Descoteaux,et al.  Macrophage Cytokines: Involvement in Immunity and Infectious Diseases , 2014, Front. Immunol..

[33]  V. Andrade-Neto,et al.  Comparative Study on the Antioxidant and Anti-Toxoplasma Activities of Vanillin and Its Resorcinarene Derivative , 2014, Molecules.

[34]  S. Chowdhury,et al.  Disuccinyl Betulin Triggers Metacaspase-Dependent Endonuclease G-Mediated Cell Death in Unicellular Protozoan Parasite Leishmania donovani , 2014, Antimicrobial Agents and Chemotherapy.

[35]  Dong Liu,et al.  The early interaction of Leishmania with macrophages and dendritic cells and its influence on the host immune response , 2012, Front. Cell. Inf. Microbio..

[36]  C. Ronco,et al.  Renal involvement in leishmaniasis: a review of the literature , 2011, NDT plus.

[37]  F. Frézard,et al.  New delivery strategies for the old pentavalent antimonial drugs , 2010, Expert opinion on drug delivery.

[38]  S. Nylén,et al.  Immunological Perspectives of Leishmaniasis , 2010, Journal of global infectious diseases.

[39]  S. Vyas,et al.  Optimizing efficacy of amphotericin B through nanomodification , 2006, International journal of nanomedicine.

[40]  P. Desjeux.  Leishmaniasis: current situation and new perspectives. , 2004, Comparative immunology, microbiology and infectious diseases.

[41]  G. Matlashewski,et al.  Immune Responses Induced by the Leishmania (Leishmania) donovani A2 Antigen, but Not by the LACK Antigen, Are Protective against Experimental Leishmania (Leishmania) amazonensis Infection , 2003, Infection and Immunity.

[42]  R. Tesh,et al.  Leishmaniases of the New World: current concepts and implications for future research , 1993, Clinical Microbiology Reviews.